viusid
Small moleculeexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
8
Phase 3
4
Phase 4
0
Earliest trial started Feb 28, 2007 (NCT00509418)
Timeline
Indications
Studied for
- Anti-Infective Agents, Local · Phase 2
- COVID-19 · Phase 2
- Diabetes Mellitus · Phase 2
- Esophageal Neoplasms · Phase 2
- Heart Diseases · Phase 2
- Hepatitis C, Chronic · Phase 3
- Immune System · Phase 2
- Immunologic Factors · Phase 2
- Inflammation · Phase 3
- Kidney Diseases · Phase 2
- Liver Diseases · Phase 2
- Lung Diseases · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 3
- Palliative Care · Phase 2
- Papillomavirus Infections · Phase 2
- Virus Diseases · Phase 2
- Warts · Phase 3
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- viusid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06437210 | N/A | Feb 15, 2022 | Catalysis SL |
| NCT04980534 | N/A | Jan 8, 2021 | Catalysis SL |
| NCT04701502 | Phase 2 | Nov 9, 2020 | Catalysis SL |
| NCT04407182 | Phase 2 | May 4, 2020 | Catalysis SL |
| NCT03584308 | Phase 2 | Oct 15, 2015 | Catalysis SL |
| NCT01111344 | Phase 3 | Dec 1, 2010 | Catalysis SL |
| NCT00978224 | Phase 3 | Oct 31, 2009 | Catalysis SL |
| NCT01008007 | Phase 2 | Sep 30, 2009 | Catalysis SL |
| NCT00778843 | Phase 3 | Oct 31, 2008 | Catalysis SL |
| NCT00509418 | Phase 3 | Feb 28, 2007 | Catalysis SL |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Catalysis SL | For profit | 10 | 10 | 3 | 2007 |
1 organizations
Page 1 / 1